| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/28/2002 | WO2002015888A1 Drug-release controlling system |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2002015867A1 Use of beta-mannosylglycerate and derivatives in cosmetic and dermatological formulations |
| 02/28/2002 | WO2002015680A1 Type iii allergic inflammation model animal |
| 02/28/2002 | WO2002009667A9 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085196A3 Cxcr4 antagonist treatment of hematopoietic cells |
| 02/28/2002 | WO2001083385A3 Devices and method for production of traceable immunizing drinking water, other liquids and gas |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001078769A3 Regulation of systemic immune responses utilizing soluble cd40 |
| 02/28/2002 | WO2001078767A3 Pharmaceutical preparations comprising modified peptides |
| 02/28/2002 | WO2001076615A3 Cxcr4 agonist treatment of hematopoietic cells |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001075064A3 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 02/28/2002 | WO2001068852A3 Apolipoprotein-a-i regulation of t-cell signalling |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001046200A8 Novel piperidine and piperazine derivatives |
| 02/28/2002 | WO2001042474A3 Interferon-like molecules and uses thereof |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001040266A3 Insect poison allergens with reduced ige reactivity and method for producing the same |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001030812A3 Activation of hcv-specific t cells |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 02/28/2002 | WO2000077037A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | US20020026056 Substituted imidazoles having cytokine inhibitory activity |
| 02/28/2002 | US20020026051 Calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity |
| 02/28/2002 | US20020025981 Synergistic mixture of amlodipine and statins |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025927 Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them |
| 02/28/2002 | US20020025516 Nrde |
| 02/28/2002 | US20020025329 For immunization |
| 02/28/2002 | US20020025325 Mixing a water soluble palatable flavorant with a water soluble vehicle for administration of an orally administered vaccine admixing with an antigen selected from bacterium and a virus as an active component; administering to animal |
| 02/28/2002 | US20020025317 For therapy and prophylaxis of pathological condition associated with expression of Interelukin-12 and/or Interleukin-18, including excessive or inappropriate amounts of those cytokines |
| 02/28/2002 | US20020025304 Novel interferon for the treatment of multiple sclerosis |
| 02/28/2002 | US20020023877 Methods for the production of D-chiro-inositol and the use of D-chiro-inositol obtained therefrom |
| 02/28/2002 | CA2678754A1 Process for the preparation and purification of thiol-containing maytansinoids |
| 02/28/2002 | CA2674888A1 Anti-ige vaccines |
| 02/28/2002 | CA2674838A1 Anti-ige vaccines |
| 02/28/2002 | CA2420526A1 Adjuvant |
| 02/28/2002 | CA2420499A1 Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420260A1 Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420087A1 Cripto tumour polypeptide |
| 02/28/2002 | CA2420086A1 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419872A1 Identification of a human n-terminal acetyltransferase gene |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419580A1 Integrin receptor inhibitors |
| 02/28/2002 | CA2419274A1 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | CA2417787A1 Lipid metabolism enzymes |
| 02/28/2002 | CA2417186A1 Microtubule-associated proteins and tubulins |
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/28/2002 | CA2356124A1 Anti-ige vaccines |
| 02/27/2002 | EP1182256A1 Pollinosis-associated gene 513 |
| 02/27/2002 | EP1181938A2 Rapamycin conjugates and antibodies |
| 02/27/2002 | EP1181937A2 Novel vaccine adjuvant and vaccine |
| 02/27/2002 | EP1181929A2 Method of potentiating an immune response and compositions therefor |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181381A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181366A1 Mammalian receptor proteins; related reagents and methods |
| 02/27/2002 | EP1181363A1 Recombinant human mannan-binding lectin |
| 02/27/2002 | EP1181320A2 Somatic transgene immunization and related methods |
| 02/27/2002 | EP1181319A1 Dr4 antibodies and uses thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181310A1 Chemokine receptor ccr3 antagonists |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181286A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181278A1 Cyclic amine derivatives and their uses |
| 02/27/2002 | EP1181276A1 Morpholino-n-ethyl ester derivative of an indole spla-2 inhibitor |
| 02/27/2002 | EP1181266A1 Squaric acid derivatives as cell adhesion molecules |
| 02/27/2002 | EP1181057A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181053A2 Use of soluble costimulatory molecules to enhance immune responses |
| 02/27/2002 | EP1181052A1 Protein a based binding domains with desirable activities |
| 02/27/2002 | EP1181051A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-MEDIATED DISEASES USING i MYCOBACTERIUM VACCAE /i |
| 02/27/2002 | EP1181050A1 Methods for preventing reactivation of latent virus and controlling virus replication |
| 02/27/2002 | EP1181047A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 02/27/2002 | EP1181038A2 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181035A2 Substantially oil-free cyclosporin compositions |
| 02/27/2002 | EP1181034A2 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 02/27/2002 | EP1181020A2 Vitamin d derivatives for the teatment of systemic lupus erythematosus |
| 02/27/2002 | EP1181016A1 Chemical compounds having ion channel blocking activity for the treatment ofimmune dysfunction |
| 02/27/2002 | EP1181014A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 02/27/2002 | EP1180999A2 Recombinant vaccine against botulinum neurotoxin |
| 02/27/2002 | EP0825991B1 Diaryldiamine derivatives and their use as delta opioid (ant)-agonists |
| 02/27/2002 | EP0817770B1 Nonpeptides as tachykinin antagonists |